Posted by Michael Wonder on 26 May 2021
Varian receives FDA breakthrough device designation for its cardiac radioablation system for treatment of refractory ventricular tachycardia
26 May 2021 - Varian's CRA system has been designated a "breakthrough device" by the FDA because of its potential to offer a more effective treatment for select patients with refractory ventricular tachycardia.
Varian announced today that the U.S. FDA has granted the company breakthrough device designation for its cardiac radioablation system, currently in development as a noninvasive therapy for select patients with refractory ventricular tachycardia.
